CARMAT says its Aeson artificial heart product will form part of French clinical study

[January 04, 2023]  PARIS (Reuters) - French healthcare and medical technology company CARMAT said on Wednesday that its Aeson artificial heart product would be implemented within the framework of a clinical study in France known as 'EFICAS'.

"EFICAS is the largest study undertaken by CARMAT at this stage, and I am delighted that it will entirely take place in France, thus enabling our country's patients to benefit from our therapy. This is a crucial study, as it will eventually notably allow us to obtain Aeson’s reimbursement in France," said CARMAT chief executive Stéphane Piat in a statement.

Chief Executive Officer of French artificial heart manufacturer Carmat, Stephane Piat, poses holding an artificial heart during an interview with Reuters in Velizy, near Paris, January 11, 2021. REUTERS/Christian Hartmann TPX IMAGES OF THE DAY

(Reporting by Sudip Kar-Gupta; Editing by Christopher Cushing)

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.